408 related articles for article (PubMed ID: 23105105)
1. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.
Karch CM; Jeng AT; Goate AM
J Biol Chem; 2012 Dec; 287(51):42751-62. PubMed ID: 23105105
[TBL] [Abstract][Full Text] [Related]
2. Cellular and pathological heterogeneity of primary tauopathies.
Chung DC; Roemer S; Petrucelli L; Dickson DW
Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
[TBL] [Abstract][Full Text] [Related]
3. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.
Silva MC; Haggarty SJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255694
[TBL] [Abstract][Full Text] [Related]
4. Genetic and sporadic forms of tauopathies-TAU as a disease driver for the majority of patients but the minority of tauopathies.
Zempel H
Cytoskeleton (Hoboken); 2024 Jan; 81(1):66-70. PubMed ID: 37795931
[TBL] [Abstract][Full Text] [Related]
5. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
6. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations.
Iovino M; Agathou S; González-Rueda A; Del Castillo Velasco-Herrera M; Borroni B; Alberici A; Lynch T; O'Dowd S; Geti I; Gaffney D; Vallier L; Paulsen O; Káradóttir RT; Spillantini MG
Brain; 2015 Nov; 138(Pt 11):3345-59. PubMed ID: 26220942
[TBL] [Abstract][Full Text] [Related]
7. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
[TBL] [Abstract][Full Text] [Related]
8. Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.
Xia Y; Sorrentino ZA; Kim JD; Strang KH; Riffe CJ; Giasson BI
J Biol Chem; 2019 Nov; 294(48):18488-18503. PubMed ID: 31653695
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
10. Tau protein in familial and sporadic diseases.
Yancopoulou D; Spillantini MG
Neuromolecular Med; 2003; 4(1-2):37-48. PubMed ID: 14528051
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of the tauopathies.
Goedert M; Spillantini MG
J Mol Neurosci; 2011 Nov; 45(3):425-31. PubMed ID: 21785996
[TBL] [Abstract][Full Text] [Related]
12. MMP-9 and MMP-2 Contribute to Neuronal Cell Death in iPSC Models of Frontotemporal Dementia with MAPT Mutations.
Biswas MHU; Almeida S; Lopez-Gonzalez R; Mao W; Zhang Z; Karydas A; Geschwind MD; Biernat J; Mandelkow EM; Futai K; Miller BL; Gao FB
Stem Cell Reports; 2016 Sep; 7(3):316-324. PubMed ID: 27594586
[TBL] [Abstract][Full Text] [Related]
13. Partial deletion of the MAPT gene: a novel mechanism of FTDP-17.
Rovelet-Lecrux A; Lecourtois M; Thomas-Anterion C; Le Ber I; Brice A; Frebourg T; Hannequin D; Campion D
Hum Mutat; 2009 Apr; 30(4):E591-602. PubMed ID: 19263483
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a
Bukhari H; Nithianandam V; Battaglia RA; Cicalo A; Sarkar S; Comjean A; Hu Y; Leventhal MJ; Dong X; Feany MB
Genome Res; 2024 May; 34(4):590-605. PubMed ID: 38599684
[TBL] [Abstract][Full Text] [Related]
15. The human MAPT locus generates circular RNAs.
Welden JR; van Doorn J; Nelson PT; Stamm S
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2753-2760. PubMed ID: 29729314
[TBL] [Abstract][Full Text] [Related]
16. Frontotemporal dementia with the V337M
Spina S; Schonhaut DR; Boeve BF; Seeley WW; Ossenkoppele R; O'Neil JP; Lazaris A; Rosen HJ; Boxer AL; Perry DC; Miller BL; Dickson DW; Parisi JE; Jagust WJ; Murray ME; Rabinovici GD
Neurology; 2017 Feb; 88(8):758-766. PubMed ID: 28130473
[TBL] [Abstract][Full Text] [Related]
17. CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation.
Ke YD; Chan G; Stefanoska K; Au C; Bi M; Müller J; Przybyla M; Feiten A; Prikas E; Halliday GM; Piguet O; Kiernan MC; Kassiou M; Hodges JR; Loy CT; Mattick JS; Ittner A; Kril JJ; Sutherland GT; Ittner LM
J Biol Chem; 2019 Sep; 294(38):14149-14162. PubMed ID: 31366728
[TBL] [Abstract][Full Text] [Related]
18. P301 L, an FTDP-17 Mutant, Exhibits Enhanced Glycation in vitro.
Sonawane SK; Chinnathambi S
J Alzheimers Dis; 2020; 75(1):61-71. PubMed ID: 32250308
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic MAPT mutations Q336H and Q336R have isoform-dependent differences in aggregation propensity and microtubule dysfunction.
Xia Y; Nasif L; Giasson BI
J Neurochem; 2021 Jul; 158(2):455-466. PubMed ID: 33772783
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies.
Akwa Y; Di Malta C; Zallo F; Gondard E; Lunati A; Diaz-de-Grenu LZ; Zampelli A; Boiret A; Santamaria S; Martinez-Preciado M; Cortese K; Kordower JH; Matute C; Lozano AM; Capetillo-Zarate E; Vaccari T; Settembre C; Baulieu EE; Tampellini D
Autophagy; 2023 Feb; 19(2):660-677. PubMed ID: 35867714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
